BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32293349)

  • 21. RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer.
    Pan Y; Tong JHM; Lung RWM; Kang W; Kwan JSH; Chak WP; Tin KY; Chung LY; Wu F; Ng SSM; Mak TWC; Yu J; Lo KW; Chan AWH; To KF
    Mol Cancer; 2018 Jul; 17(1):102. PubMed ID: 30037330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway.
    Sun X; Zhang Y; Xin S; Jin L; Cao Q; Wang H; Wang K; Liu X; Tang C; Li W; Li Z; Wen X; Yang G; Guo C; Liu Z; Ye L
    Cancer Sci; 2024 Feb; 115(2):412-426. PubMed ID: 38115797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
    Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
    BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
    Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
    Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
    Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant chemohormonal therapy followed by robot-assisted and minimum incision endoscopic radical prostatectomy in patients with high-risk prostate cancer: comparison of perioperative and oncological outcomes at single institution.
    Fujita N; Koie T; Hashimoto Y; Narita T; Tobisawa Y; Tanaka T; Noro D; Oikawa M; Hagiwara K; Yoneyama T; Imai A; Yamamoto H; Hatakeyama S; Yoneyama T; Ohyama C
    Int Urol Nephrol; 2018 Nov; 50(11):1999-2005. PubMed ID: 30229466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.
    Nguyen LT; Tretiakova MS; Silvis MR; Lucas J; Klezovitch O; Coleman I; Bolouri H; Kutyavin VI; Morrissey C; True LD; Nelson PS; Vasioukhin V
    Cancer Cell; 2015 Jun; 27(6):797-808. PubMed ID: 26058078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
    Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
    Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells.
    Wu Y; Zheng Q; Li Y; Wang G; Gao S; Zhang X; Yan X; Zhang X; Xie J; Wang Y; Sun X; Meng X; Yin B; Wang B
    J Exp Clin Cancer Res; 2019 Aug; 38(1):376. PubMed ID: 31455378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
    Ma Z; Zhang W; Dong B; Xin Z; Ji Y; Su R; Shen K; Pan J; Wang Q; Xue W
    Theranostics; 2022; 12(11):4965-4979. PubMed ID: 35836810
    [No Abstract]   [Full Text] [Related]  

  • 31. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis.
    Kang W; Huang T; Zhou Y; Zhang J; Lung RWM; Tong JHM; Chan AWH; Zhang B; Wong CC; Wu F; Dong Y; Wang S; Yang W; Pan Y; Chak WP; Cheung AHK; Pang JCS; Yu J; Cheng ASL; To KF
    Cell Death Dis; 2018 Jan; 9(2):92. PubMed ID: 29367737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. YAP is closely correlated with castration-resistant prostate cancer, and downregulation of YAP reduces proliferation and induces apoptosis of PC-3 cells.
    Sheng X; Li WB; Wang DL; Chen KH; Cao JJ; Luo Z; He J; Li MC; Liu WJ; Yu C
    Mol Med Rep; 2015 Oct; 12(4):4867-76. PubMed ID: 26126522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.
    Kroon J; Puhr M; Buijs JT; van der Horst G; Hemmer DM; Marijt KA; Hwang MS; Masood M; Grimm S; Storm G; Metselaar JM; Meijer OC; Culig Z; van der Pluijm G
    Endocr Relat Cancer; 2016 Jan; 23(1):35-45. PubMed ID: 26483423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
    Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
    Zeng J; Liu W; Fan YZ; He DL; Li L
    Theranostics; 2018; 8(1):109-123. PubMed ID: 29290796
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.
    Matsumoto T; Hatakeyama S; Ookubo T; Mitsuzuka K; Narita S; Inoue T; Yamashita S; Narita T; Koie T; Kawamura S; Tochigi T; Tsuchiya N; Habuchi T; Arai Y; Ohyama C
    Med Oncol; 2017 Oct; 34(12):190. PubMed ID: 29090390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant chemohormonal therapy before radical prostatectomy in high-risk prostate cancer: a mini-review.
    Fan J; Jiang Z; Wang G; He D; Wu K
    Am J Clin Exp Urol; 2024; 12(1):1-7. PubMed ID: 38500864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The association between the expression of nuclear Yes-associated protein 1 (YAP1) and p53 protein expression profile in breast cancer patients.
    Cha YJ; Kim D; Bae SJ; Ahn SG; Jeong J; Cho MK; Paik PS; Yoo TK; Park WC; Yoon CI
    PLoS One; 2021; 16(5):e0250986. PubMed ID: 33970925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Up-regulated acylglycerol kinase (AGK) expression associates with gastric cancer progression through the formation of a novel YAP1-AGK-positive loop.
    Huang S; Cao Y; Guo H; Yao Y; Li L; Chen J; Li J; Xiang X; Deng J; Xiong J
    J Cell Mol Med; 2020 Oct; 24(19):11133-11145. PubMed ID: 32827244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy.
    Pietzak EJ; Eastham JA
    Curr Urol Rep; 2016 May; 17(5):37. PubMed ID: 26968417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.